Adcendo ApSDanish ADC maker Adcendo ApS has licenced the rights to commercialise Multitude Therapeutics Inc’s first-in-class ADCE-T02 globally except the Greater China region.
Tag Archive for: ADC
Medilink TherapeuticsGood news for BioNTech SE: The safety study of the ADC BNT326/YL202 developed by MediLink Therapeutics, which was suspended by the FDA in mid-June, will continue.
Biocytogen Co LtdCzech Sotio Biotech has inked an R&D and licence option agreement with Chinese antibody maker Biocytogen.
Tubulis GmbHTubulis doses first patient in phase 1/2a trial investigating ADC candidate TUB-040 in ovarian cancer and lung adenocarcinoma (NSCLC). TUB-040 is a NaPi2b-targeting Exatecan ADC based on Tubulis’ proprietary linker technology with better biophysical properties that demonstrated effective and durable responses in a range of preclinical models.
Glycan target specialist Tacalyx GmbH expands its seed financing to €14m to advance its anti-TACA cancer therapies.
Genmab announced today that it will acquire privately held biotech company ProfoundBio for $1.8bn in cash. The deal is designed to help the Danish pharmaceutical company deepen its cancer pipeline with next-generation antibody-drug conjugate therapies where the company has already an inlicensing deal with former Synaffix´s ADC technology platform (which was acquired mid of 2023 by Lonza).
AbbVie buys ImmunoGen in US$10 billion deal, gains access to ADC for ovarian cancer. The ADC space gets hotter and hotter.
Sotio hsd licenced Synaffix’ ADC platform for up to US$740m to develop up to three next generation bioconjugates.
Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting Claudin-1 (CLDN1). The molecule is significantly involved in the tight junction between cells. Now the company closed a three digit million Seriec C round.
Genmab and argenx have entered a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialise antibody therapies.